Source Name	Characteristics[sample_name]	Characteristics[organism]	Characteristics[taxonomy_id]	Characteristics[isolate]	Characteristics[biomaterial_provider]	Characteristics[collection_date]	Characteristics[geo_loc_name]	Characteristics[age]	Characteristics[disease]	Characteristics[sex]	Characteristics[tissue]	Comment[BioSample]	Comment[sample_title]	Comment[description]	Protocol REF	Protocol REF	Protocol REF	Extract Name	Material Type	Comment[LIBRARY_LAYOUT]	Comment[LIBRARY_SELECTION]	Comment[LIBRARY_SOURCE]	Comment[LIBRARY_STRATEGY]	Comment[INSTRUMENT_MODEL]	Protocol REF	Assay Name	Comment[SRA_EXPERIMENT]	Comment[SRA_RUN]	Technology Type	Array Data File	Protocol REF	Derived Array Data File	Factor Value[cell_type]	Factor Value[antibody]	Factor Value[genetic_modification]
Sample0503	Sample0503	Homo sapiens	9606	not collected	Cellular Technology Limited	not collected	not collected	not collected	healthy_mixture_9	not collected	Peripheral Blood Mononuclear Cells	SAMD00641100	Sample_inChIP_Ctrl	Naive CD4 Tconv cells were sorted from PBMC (Day 0). Cells were stimulated with plate-bound anti-human CD3 (10 ug/mL; clone UCHT1) and anti-human CD28 (5 ug/mL; clone CD28.2). Cells were transduced with titrated lentivirus encoding eGFP mock vector 24 hours post-stimulation (Day 1). At Day 3, cells were collected and resuspended with freshly prepared medium including 500 IU/mL of hIL-2 (Day 3) and expanded for 6 days. CD4 Tconv cells were stimulated for 72 hours using Dynabeads Human T-Activator CD3/CD28 (Thermo Fisher, #11131D) at a 1:1 ratio and supplemented with 500 IU/mL of hIL-2 (R&D Systems), 5 ng/mL of hTGF-b (R&D Systems), 10 ug/mL of Ascorbate (Sigma-Aldrich), 10 nM of ATRA (Sigma-Aldrich), 5 ug/mL of anti-hIFN-g, -hIL-4, -hIL-6 and -hTNF-a (BioLegend) antibodies and 5 ug/mL of anti-FasL (BioLegend) antibodies in complete culture medium.	P-GEAD-1993	P-GEAD-1994	P-GEAD-1995	Sample0503	total RNA	PAIRED	other	GENOMIC	CH_IP_SEQ	Illumina NovaSeq 6000	P-GEAD-1996	inChIP_H3ac_Foxp3nega_rep1	DRX484411	DRR500306	sequencing assay	DRR500306	P-GEAD-1997	DRR500306.tar.gz	Foxp3-negative Tregs	H3ac	Mock
Sample0503	Sample0503	Homo sapiens	9606	not collected	Cellular Technology Limited	not collected	not collected	not collected	healthy_mixture_9	not collected	Peripheral Blood Mononuclear Cells	SAMD00641100	Sample_inChIP_Ctrl	Naive CD4 Tconv cells were sorted from PBMC (Day 0). Cells were stimulated with plate-bound anti-human CD3 (10 ug/mL; clone UCHT1) and anti-human CD28 (5 ug/mL; clone CD28.2). Cells were transduced with titrated lentivirus encoding eGFP mock vector 24 hours post-stimulation (Day 1). At Day 3, cells were collected and resuspended with freshly prepared medium including 500 IU/mL of hIL-2 (Day 3) and expanded for 6 days. CD4 Tconv cells were stimulated for 72 hours using Dynabeads Human T-Activator CD3/CD28 (Thermo Fisher, #11131D) at a 1:1 ratio and supplemented with 500 IU/mL of hIL-2 (R&D Systems), 5 ng/mL of hTGF-b (R&D Systems), 10 ug/mL of Ascorbate (Sigma-Aldrich), 10 nM of ATRA (Sigma-Aldrich), 5 ug/mL of anti-hIFN-g, -hIL-4, -hIL-6 and -hTNF-a (BioLegend) antibodies and 5 ug/mL of anti-FasL (BioLegend) antibodies in complete culture medium.	P-GEAD-1993	P-GEAD-1994	P-GEAD-1995	Sample0503	total RNA	PAIRED	other	GENOMIC	CH_IP_SEQ	Illumina NovaSeq 6000	P-GEAD-1996	inChIP_H3ac_Foxp3nega_rep2	DRX484411	DRR500307	sequencing assay	DRR500307	P-GEAD-1997	DRR500307.tar.gz	Foxp3-negative Tregs	H3ac	Mock
Sample0503	Sample0503	Homo sapiens	9606	not collected	Cellular Technology Limited	not collected	not collected	not collected	healthy_mixture_9	not collected	Peripheral Blood Mononuclear Cells	SAMD00641100	Sample_inChIP_Ctrl	Naive CD4 Tconv cells were sorted from PBMC (Day 0). Cells were stimulated with plate-bound anti-human CD3 (10 ug/mL; clone UCHT1) and anti-human CD28 (5 ug/mL; clone CD28.2). Cells were transduced with titrated lentivirus encoding eGFP mock vector 24 hours post-stimulation (Day 1). At Day 3, cells were collected and resuspended with freshly prepared medium including 500 IU/mL of hIL-2 (Day 3) and expanded for 6 days. CD4 Tconv cells were stimulated for 72 hours using Dynabeads Human T-Activator CD3/CD28 (Thermo Fisher, #11131D) at a 1:1 ratio and supplemented with 500 IU/mL of hIL-2 (R&D Systems), 5 ng/mL of hTGF-b (R&D Systems), 10 ug/mL of Ascorbate (Sigma-Aldrich), 10 nM of ATRA (Sigma-Aldrich), 5 ug/mL of anti-hIFN-g, -hIL-4, -hIL-6 and -hTNF-a (BioLegend) antibodies and 5 ug/mL of anti-FasL (BioLegend) antibodies in complete culture medium.	P-GEAD-1993	P-GEAD-1994	P-GEAD-1995	Sample0503	total RNA	PAIRED	other	GENOMIC	CH_IP_SEQ	Illumina NovaSeq 6000	P-GEAD-1996	inChIP_H3ac_Foxp3nega_rep3	DRX484411	DRR500308	sequencing assay	DRR500308	P-GEAD-1997	DRR500308.tar.gz	Foxp3-negative Tregs	H3ac	Mock
Sample0503	Sample0503	Homo sapiens	9606	not collected	Cellular Technology Limited	not collected	not collected	not collected	healthy_mixture_9	not collected	Peripheral Blood Mononuclear Cells	SAMD00641100	Sample_inChIP_Ctrl	Naive CD4 Tconv cells were sorted from PBMC (Day 0). Cells were stimulated with plate-bound anti-human CD3 (10 ug/mL; clone UCHT1) and anti-human CD28 (5 ug/mL; clone CD28.2). Cells were transduced with titrated lentivirus encoding eGFP mock vector 24 hours post-stimulation (Day 1). At Day 3, cells were collected and resuspended with freshly prepared medium including 500 IU/mL of hIL-2 (Day 3) and expanded for 6 days. CD4 Tconv cells were stimulated for 72 hours using Dynabeads Human T-Activator CD3/CD28 (Thermo Fisher, #11131D) at a 1:1 ratio and supplemented with 500 IU/mL of hIL-2 (R&D Systems), 5 ng/mL of hTGF-b (R&D Systems), 10 ug/mL of Ascorbate (Sigma-Aldrich), 10 nM of ATRA (Sigma-Aldrich), 5 ug/mL of anti-hIFN-g, -hIL-4, -hIL-6 and -hTNF-a (BioLegend) antibodies and 5 ug/mL of anti-FasL (BioLegend) antibodies in complete culture medium.	P-GEAD-1993	P-GEAD-1994	P-GEAD-1995	Sample0503	total RNA	PAIRED	other	GENOMIC	CH_IP_SEQ	Illumina NovaSeq 6000	P-GEAD-1996	inChIP_H3ac_Foxp3posi_rep1	DRX484411	DRR500309	sequencing assay	DRR500309	P-GEAD-1997	DRR500309.tar.gz	Foxp3-positive Tregs	H3ac	Mock
Sample0503	Sample0503	Homo sapiens	9606	not collected	Cellular Technology Limited	not collected	not collected	not collected	healthy_mixture_9	not collected	Peripheral Blood Mononuclear Cells	SAMD00641100	Sample_inChIP_Ctrl	Naive CD4 Tconv cells were sorted from PBMC (Day 0). Cells were stimulated with plate-bound anti-human CD3 (10 ug/mL; clone UCHT1) and anti-human CD28 (5 ug/mL; clone CD28.2). Cells were transduced with titrated lentivirus encoding eGFP mock vector 24 hours post-stimulation (Day 1). At Day 3, cells were collected and resuspended with freshly prepared medium including 500 IU/mL of hIL-2 (Day 3) and expanded for 6 days. CD4 Tconv cells were stimulated for 72 hours using Dynabeads Human T-Activator CD3/CD28 (Thermo Fisher, #11131D) at a 1:1 ratio and supplemented with 500 IU/mL of hIL-2 (R&D Systems), 5 ng/mL of hTGF-b (R&D Systems), 10 ug/mL of Ascorbate (Sigma-Aldrich), 10 nM of ATRA (Sigma-Aldrich), 5 ug/mL of anti-hIFN-g, -hIL-4, -hIL-6 and -hTNF-a (BioLegend) antibodies and 5 ug/mL of anti-FasL (BioLegend) antibodies in complete culture medium.	P-GEAD-1993	P-GEAD-1994	P-GEAD-1995	Sample0503	total RNA	PAIRED	other	GENOMIC	CH_IP_SEQ	Illumina NovaSeq 6000	P-GEAD-1996	inChIP_H3ac_Foxp3posi_rep2	DRX484411	DRR500310	sequencing assay	DRR500310	P-GEAD-1997	DRR500310.tar.gz	Foxp3-positive Tregs	H3ac	Mock
Sample0503	Sample0503	Homo sapiens	9606	not collected	Cellular Technology Limited	not collected	not collected	not collected	healthy_mixture_9	not collected	Peripheral Blood Mononuclear Cells	SAMD00641100	Sample_inChIP_Ctrl	Naive CD4 Tconv cells were sorted from PBMC (Day 0). Cells were stimulated with plate-bound anti-human CD3 (10 ug/mL; clone UCHT1) and anti-human CD28 (5 ug/mL; clone CD28.2). Cells were transduced with titrated lentivirus encoding eGFP mock vector 24 hours post-stimulation (Day 1). At Day 3, cells were collected and resuspended with freshly prepared medium including 500 IU/mL of hIL-2 (Day 3) and expanded for 6 days. CD4 Tconv cells were stimulated for 72 hours using Dynabeads Human T-Activator CD3/CD28 (Thermo Fisher, #11131D) at a 1:1 ratio and supplemented with 500 IU/mL of hIL-2 (R&D Systems), 5 ng/mL of hTGF-b (R&D Systems), 10 ug/mL of Ascorbate (Sigma-Aldrich), 10 nM of ATRA (Sigma-Aldrich), 5 ug/mL of anti-hIFN-g, -hIL-4, -hIL-6 and -hTNF-a (BioLegend) antibodies and 5 ug/mL of anti-FasL (BioLegend) antibodies in complete culture medium.	P-GEAD-1993	P-GEAD-1994	P-GEAD-1995	Sample0503	total RNA	PAIRED	other	GENOMIC	CH_IP_SEQ	Illumina NovaSeq 6000	P-GEAD-1996	inChIP_H3ac_Foxp3posi_rep3	DRX484411	DRR500311	sequencing assay	DRR500311	P-GEAD-1997	DRR500311.tar.gz	Foxp3-positive Tregs	H3ac	Mock
Sample0501	Sample0501	Homo sapiens	9606	not collected	Cellular Technology Limited	not collected	not collected	not collected	healthy_mixture_7	not collected	Peripheral Blood Mononuclear Cells	SAMD00641098	Sample_inChIP_RBPJ_MT	Naive CD4 Tconv cells were sorted from PBMC (Day 0). Cells were stimulated with plate-bound anti-human CD3 (10 ug/mL; clone UCHT1) and anti-human CD28 (5 ug/mL; clone CD28.2). Cells were transduced with titrated lentivirus encoding mutant RBPJ 24 hours post-stimulation (Day 1). At Day 3, cells were collected and resuspended with freshly prepared medium including 500 IU/mL of hIL-2 (Day 3) and expanded for 6 days. CD4 Tconv cells were stimulated for 72 hours using Dynabeads Human T-Activator CD3/CD28 (Thermo Fisher, #11131D) at a 1:1 ratio and supplemented with 500 IU/mL of hIL-2 (R&D Systems), 5 ng/mL of hTGF-b (R&D Systems), 10 ug/mL of Ascorbate (Sigma-Aldrich), 10 nM of ATRA (Sigma-Aldrich), 5 ug/mL of anti-hIFN-g, -hIL-4, -hIL-6 and -hTNF-a (BioLegend) antibodies and 5 ug/mL of anti-FasL (BioLegend) antibodies in complete culture medium.	P-GEAD-1993	P-GEAD-1994	P-GEAD-1995	Sample0501	total RNA	PAIRED	other	GENOMIC	CH_IP_SEQ	Illumina NovaSeq 6000	P-GEAD-1996	inChIP_H3ac_Foxp3posi_RBPJ_MT_rep1	DRX484409	DRR500312	sequencing assay	DRR500312	P-GEAD-1997	DRR500312.tar.gz	Foxp3-positive Tregs	H3ac	F235A/L362A mutant RBPJ-AM
Sample0501	Sample0501	Homo sapiens	9606	not collected	Cellular Technology Limited	not collected	not collected	not collected	healthy_mixture_7	not collected	Peripheral Blood Mononuclear Cells	SAMD00641098	Sample_inChIP_RBPJ_MT	Naive CD4 Tconv cells were sorted from PBMC (Day 0). Cells were stimulated with plate-bound anti-human CD3 (10 ug/mL; clone UCHT1) and anti-human CD28 (5 ug/mL; clone CD28.2). Cells were transduced with titrated lentivirus encoding mutant RBPJ 24 hours post-stimulation (Day 1). At Day 3, cells were collected and resuspended with freshly prepared medium including 500 IU/mL of hIL-2 (Day 3) and expanded for 6 days. CD4 Tconv cells were stimulated for 72 hours using Dynabeads Human T-Activator CD3/CD28 (Thermo Fisher, #11131D) at a 1:1 ratio and supplemented with 500 IU/mL of hIL-2 (R&D Systems), 5 ng/mL of hTGF-b (R&D Systems), 10 ug/mL of Ascorbate (Sigma-Aldrich), 10 nM of ATRA (Sigma-Aldrich), 5 ug/mL of anti-hIFN-g, -hIL-4, -hIL-6 and -hTNF-a (BioLegend) antibodies and 5 ug/mL of anti-FasL (BioLegend) antibodies in complete culture medium.	P-GEAD-1993	P-GEAD-1994	P-GEAD-1995	Sample0501	total RNA	PAIRED	other	GENOMIC	CH_IP_SEQ	Illumina NovaSeq 6000	P-GEAD-1996	inChIP_H3ac_Foxp3posi_RBPJ_MT_rep2	DRX484409	DRR500313	sequencing assay	DRR500313	P-GEAD-1997	DRR500313.tar.gz	Foxp3-positive Tregs	H3ac	F235A/L362A mutant RBPJ-AM
Sample0502	Sample0502	Homo sapiens	9606	not collected	Cellular Technology Limited	not collected	not collected	not collected	healthy_mixture_8	not collected	Peripheral Blood Mononuclear Cells	SAMD00641099	Sample_inChIP_RBPJ_WT	Naive CD4 Tconv cells were sorted from PBMC (Day 0). Cells were stimulated with plate-bound anti-human CD3 (10 ug/mL; clone UCHT1) and anti-human CD28 (5 ug/mL; clone CD28.2). Cells were transduced with titrated lentivirus encoding WT RBPJ 24 hours post-stimulation (Day 1). At Day 3, cells were collected and resuspended with freshly prepared medium including 500 IU/mL of hIL-2 (Day 3) and expanded for 6 days. CD4 Tconv cells were stimulated for 72 hours using Dynabeads Human T-Activator CD3/CD28 (Thermo Fisher, #11131D) at a 1:1 ratio and supplemented with 500 IU/mL of hIL-2 (R&D Systems), 5 ng/mL of hTGF-b (R&D Systems), 10 ug/mL of Ascorbate (Sigma-Aldrich), 10 nM of ATRA (Sigma-Aldrich), 5 ug/mL of anti-hIFN-g, -hIL-4, -hIL-6 and -hTNF-a (BioLegend) antibodies and 5 ug/mL of anti-FasL (BioLegend) antibodies in complete culture medium.	P-GEAD-1993	P-GEAD-1994	P-GEAD-1995	Sample0502	total RNA	PAIRED	other	GENOMIC	CH_IP_SEQ	Illumina NovaSeq 6000	P-GEAD-1996	inChIP_H3ac_Foxp3posi_RBPJ_WT_rep1	DRX484410	DRR500314	sequencing assay	DRR500314	P-GEAD-1997	DRR500314.tar.gz	Foxp3-positive Tregs	H3ac	wild-type RBPJ-AM
@@10@@Sample0502	Sample0502	Homo sapiens	9606	not collected	Cellular Technology Limited	not collected	not collected	not collected	healthy_mixture_8	not collected	Peripheral Blood Mononuclear Cells	SAMD00641099	Sample_inChIP_RBPJ_WT	Naive CD4 Tconv cells were sorted from PBMC (Day 0). Cells were stimulated with plate-bound anti-human CD3 (10 ug/mL; clone UCHT1) and anti-human CD28 (5 ug/mL; clone CD28.2). Cells were transduced with titrated lentivirus encoding WT RBPJ 24 hours post-stimulation (Day 1). At Day 3, cells were collected and resuspended with freshly prepared medium including 500 IU/mL of hIL-2 (Day 3) and expanded for 6 days. CD4 Tconv cells were stimulated for 72 hours using Dynabeads Human T-Activator CD3/CD28 (Thermo Fisher, #11131D) at a 1:1 ratio and supplemented with 500 IU/mL of hIL-2 (R&D Systems), 5 ng/mL of hTGF-b (R&D Systems), 10 ug/mL of Ascorbate (Sigma-Aldrich), 10 nM of ATRA (Sigma-Aldrich), 5 ug/mL of anti-hIFN-g, -hIL-4, -hIL-6 and -hTNF-a (BioLegend) antibodies and 5 ug/mL of anti-FasL (BioLegend) antibodies in complete culture medium.	P-GEAD-1993	P-GEAD-1994	P-GEAD-1995	Sample0502	total RNA	PAIRED	other	GENOMIC	CH_IP_SEQ	Illumina NovaSeq 6000	P-GEAD-1996	inChIP_H3ac_Foxp3posi_RBPJ_WT_rep2	DRX484410	DRR500315	sequencing assay	DRR500315	P-GEAD-1997	DRR500315.tar.gz	Foxp3-positive Tregs	H3ac	wild-type RBPJ-AM
@@11@@Sample0502	Sample0502	Homo sapiens	9606	not collected	Cellular Technology Limited	not collected	not collected	not collected	healthy_mixture_8	not collected	Peripheral Blood Mononuclear Cells	SAMD00641099	Sample_inChIP_RBPJ_WT	Naive CD4 Tconv cells were sorted from PBMC (Day 0). Cells were stimulated with plate-bound anti-human CD3 (10 ug/mL; clone UCHT1) and anti-human CD28 (5 ug/mL; clone CD28.2). Cells were transduced with titrated lentivirus encoding WT RBPJ 24 hours post-stimulation (Day 1). At Day 3, cells were collected and resuspended with freshly prepared medium including 500 IU/mL of hIL-2 (Day 3) and expanded for 6 days. CD4 Tconv cells were stimulated for 72 hours using Dynabeads Human T-Activator CD3/CD28 (Thermo Fisher, #11131D) at a 1:1 ratio and supplemented with 500 IU/mL of hIL-2 (R&D Systems), 5 ng/mL of hTGF-b (R&D Systems), 10 ug/mL of Ascorbate (Sigma-Aldrich), 10 nM of ATRA (Sigma-Aldrich), 5 ug/mL of anti-hIFN-g, -hIL-4, -hIL-6 and -hTNF-a (BioLegend) antibodies and 5 ug/mL of anti-FasL (BioLegend) antibodies in complete culture medium.	P-GEAD-1993	P-GEAD-1994	P-GEAD-1995	Sample0502	total RNA	PAIRED	other	GENOMIC	CH_IP_SEQ	Illumina NovaSeq 6000	P-GEAD-1996	inChIP_H3ac_Foxp3posi_RBPJ_WT_rep3	DRX484410	DRR500316	sequencing assay	DRR500316	P-GEAD-1997	DRR500316.tar.gz	Foxp3-positive Tregs	H3ac	wild-type RBPJ-AM
@@12@@Sample0502	Sample0502	Homo sapiens	9606	not collected	Cellular Technology Limited	not collected	not collected	not collected	healthy_mixture_8	not collected	Peripheral Blood Mononuclear Cells	SAMD00641099	Sample_inChIP_RBPJ_WT	Naive CD4 Tconv cells were sorted from PBMC (Day 0). Cells were stimulated with plate-bound anti-human CD3 (10 ug/mL; clone UCHT1) and anti-human CD28 (5 ug/mL; clone CD28.2). Cells were transduced with titrated lentivirus encoding WT RBPJ 24 hours post-stimulation (Day 1). At Day 3, cells were collected and resuspended with freshly prepared medium including 500 IU/mL of hIL-2 (Day 3) and expanded for 6 days. CD4 Tconv cells were stimulated for 72 hours using Dynabeads Human T-Activator CD3/CD28 (Thermo Fisher, #11131D) at a 1:1 ratio and supplemented with 500 IU/mL of hIL-2 (R&D Systems), 5 ng/mL of hTGF-b (R&D Systems), 10 ug/mL of Ascorbate (Sigma-Aldrich), 10 nM of ATRA (Sigma-Aldrich), 5 ug/mL of anti-hIFN-g, -hIL-4, -hIL-6 and -hTNF-a (BioLegend) antibodies and 5 ug/mL of anti-FasL (BioLegend) antibodies in complete culture medium.	P-GEAD-1993	P-GEAD-1994	P-GEAD-1995	Sample0502	total RNA	PAIRED	other	GENOMIC	CH_IP_SEQ	Illumina NovaSeq 6000	P-GEAD-1996	inChIP_H3ac_Foxp3posi_RBPJ_WT_rep4	DRX484410	DRR500317	sequencing assay	DRR500317	P-GEAD-1997	DRR500317.tar.gz	Foxp3-positive Tregs	H3ac	wild-type RBPJ-AM
@@13@@Sample0503	Sample0503	Homo sapiens	9606	not collected	Cellular Technology Limited	not collected	not collected	not collected	healthy_mixture_9	not collected	Peripheral Blood Mononuclear Cells	SAMD00641100	Sample_inChIP_Ctrl	Naive CD4 Tconv cells were sorted from PBMC (Day 0). Cells were stimulated with plate-bound anti-human CD3 (10 ug/mL; clone UCHT1) and anti-human CD28 (5 ug/mL; clone CD28.2). Cells were transduced with titrated lentivirus encoding eGFP mock vector 24 hours post-stimulation (Day 1). At Day 3, cells were collected and resuspended with freshly prepared medium including 500 IU/mL of hIL-2 (Day 3) and expanded for 6 days. CD4 Tconv cells were stimulated for 72 hours using Dynabeads Human T-Activator CD3/CD28 (Thermo Fisher, #11131D) at a 1:1 ratio and supplemented with 500 IU/mL of hIL-2 (R&D Systems), 5 ng/mL of hTGF-b (R&D Systems), 10 ug/mL of Ascorbate (Sigma-Aldrich), 10 nM of ATRA (Sigma-Aldrich), 5 ug/mL of anti-hIFN-g, -hIL-4, -hIL-6 and -hTNF-a (BioLegend) antibodies and 5 ug/mL of anti-FasL (BioLegend) antibodies in complete culture medium.	P-GEAD-1993	P-GEAD-1994	P-GEAD-1995	Sample0503	total RNA	PAIRED	other	GENOMIC	CH_IP_SEQ	Illumina NovaSeq 6000	P-GEAD-1996	inChIP_H3K9ac_Foxp3nega_rep1	DRX484411	DRR500318	sequencing assay	DRR500318	P-GEAD-1997	DRR500318.tar.gz	Foxp3-negative Tregs	H3K9ac	Mock
@@14@@Sample0503	Sample0503	Homo sapiens	9606	not collected	Cellular Technology Limited	not collected	not collected	not collected	healthy_mixture_9	not collected	Peripheral Blood Mononuclear Cells	SAMD00641100	Sample_inChIP_Ctrl	Naive CD4 Tconv cells were sorted from PBMC (Day 0). Cells were stimulated with plate-bound anti-human CD3 (10 ug/mL; clone UCHT1) and anti-human CD28 (5 ug/mL; clone CD28.2). Cells were transduced with titrated lentivirus encoding eGFP mock vector 24 hours post-stimulation (Day 1). At Day 3, cells were collected and resuspended with freshly prepared medium including 500 IU/mL of hIL-2 (Day 3) and expanded for 6 days. CD4 Tconv cells were stimulated for 72 hours using Dynabeads Human T-Activator CD3/CD28 (Thermo Fisher, #11131D) at a 1:1 ratio and supplemented with 500 IU/mL of hIL-2 (R&D Systems), 5 ng/mL of hTGF-b (R&D Systems), 10 ug/mL of Ascorbate (Sigma-Aldrich), 10 nM of ATRA (Sigma-Aldrich), 5 ug/mL of anti-hIFN-g, -hIL-4, -hIL-6 and -hTNF-a (BioLegend) antibodies and 5 ug/mL of anti-FasL (BioLegend) antibodies in complete culture medium.	P-GEAD-1993	P-GEAD-1994	P-GEAD-1995	Sample0503	total RNA	PAIRED	other	GENOMIC	CH_IP_SEQ	Illumina NovaSeq 6000	P-GEAD-1996	inChIP_H3K9ac_Foxp3nega_rep2	DRX484411	DRR500319	sequencing assay	DRR500319	P-GEAD-1997	DRR500319.tar.gz	Foxp3-negative Tregs	H3K9ac	Mock
@@15@@Sample0503	Sample0503	Homo sapiens	9606	not collected	Cellular Technology Limited	not collected	not collected	not collected	healthy_mixture_9	not collected	Peripheral Blood Mononuclear Cells	SAMD00641100	Sample_inChIP_Ctrl	Naive CD4 Tconv cells were sorted from PBMC (Day 0). Cells were stimulated with plate-bound anti-human CD3 (10 ug/mL; clone UCHT1) and anti-human CD28 (5 ug/mL; clone CD28.2). Cells were transduced with titrated lentivirus encoding eGFP mock vector 24 hours post-stimulation (Day 1). At Day 3, cells were collected and resuspended with freshly prepared medium including 500 IU/mL of hIL-2 (Day 3) and expanded for 6 days. CD4 Tconv cells were stimulated for 72 hours using Dynabeads Human T-Activator CD3/CD28 (Thermo Fisher, #11131D) at a 1:1 ratio and supplemented with 500 IU/mL of hIL-2 (R&D Systems), 5 ng/mL of hTGF-b (R&D Systems), 10 ug/mL of Ascorbate (Sigma-Aldrich), 10 nM of ATRA (Sigma-Aldrich), 5 ug/mL of anti-hIFN-g, -hIL-4, -hIL-6 and -hTNF-a (BioLegend) antibodies and 5 ug/mL of anti-FasL (BioLegend) antibodies in complete culture medium.	P-GEAD-1993	P-GEAD-1994	P-GEAD-1995	Sample0503	total RNA	PAIRED	other	GENOMIC	CH_IP_SEQ	Illumina NovaSeq 6000	P-GEAD-1996	inChIP_H3K9ac_Foxp3posi_rep1	DRX484411	DRR500320	sequencing assay	DRR500320	P-GEAD-1997	DRR500320.tar.gz	Foxp3-positive Tregs	H3K9ac	Mock
@@16@@Sample0503	Sample0503	Homo sapiens	9606	not collected	Cellular Technology Limited	not collected	not collected	not collected	healthy_mixture_9	not collected	Peripheral Blood Mononuclear Cells	SAMD00641100	Sample_inChIP_Ctrl	Naive CD4 Tconv cells were sorted from PBMC (Day 0). Cells were stimulated with plate-bound anti-human CD3 (10 ug/mL; clone UCHT1) and anti-human CD28 (5 ug/mL; clone CD28.2). Cells were transduced with titrated lentivirus encoding eGFP mock vector 24 hours post-stimulation (Day 1). At Day 3, cells were collected and resuspended with freshly prepared medium including 500 IU/mL of hIL-2 (Day 3) and expanded for 6 days. CD4 Tconv cells were stimulated for 72 hours using Dynabeads Human T-Activator CD3/CD28 (Thermo Fisher, #11131D) at a 1:1 ratio and supplemented with 500 IU/mL of hIL-2 (R&D Systems), 5 ng/mL of hTGF-b (R&D Systems), 10 ug/mL of Ascorbate (Sigma-Aldrich), 10 nM of ATRA (Sigma-Aldrich), 5 ug/mL of anti-hIFN-g, -hIL-4, -hIL-6 and -hTNF-a (BioLegend) antibodies and 5 ug/mL of anti-FasL (BioLegend) antibodies in complete culture medium.	P-GEAD-1993	P-GEAD-1994	P-GEAD-1995	Sample0503	total RNA	PAIRED	other	GENOMIC	CH_IP_SEQ	Illumina NovaSeq 6000	P-GEAD-1996	inChIP_H3K9ac_Foxp3posi_rep2	DRX484411	DRR500321	sequencing assay	DRR500321	P-GEAD-1997	DRR500321.tar.gz	Foxp3-positive Tregs	H3K9ac	Mock
@@17@@Sample0501	Sample0501	Homo sapiens	9606	not collected	Cellular Technology Limited	not collected	not collected	not collected	healthy_mixture_7	not collected	Peripheral Blood Mononuclear Cells	SAMD00641098	Sample_inChIP_RBPJ_MT	Naive CD4 Tconv cells were sorted from PBMC (Day 0). Cells were stimulated with plate-bound anti-human CD3 (10 ug/mL; clone UCHT1) and anti-human CD28 (5 ug/mL; clone CD28.2). Cells were transduced with titrated lentivirus encoding mutant RBPJ 24 hours post-stimulation (Day 1). At Day 3, cells were collected and resuspended with freshly prepared medium including 500 IU/mL of hIL-2 (Day 3) and expanded for 6 days. CD4 Tconv cells were stimulated for 72 hours using Dynabeads Human T-Activator CD3/CD28 (Thermo Fisher, #11131D) at a 1:1 ratio and supplemented with 500 IU/mL of hIL-2 (R&D Systems), 5 ng/mL of hTGF-b (R&D Systems), 10 ug/mL of Ascorbate (Sigma-Aldrich), 10 nM of ATRA (Sigma-Aldrich), 5 ug/mL of anti-hIFN-g, -hIL-4, -hIL-6 and -hTNF-a (BioLegend) antibodies and 5 ug/mL of anti-FasL (BioLegend) antibodies in complete culture medium.	P-GEAD-1993	P-GEAD-1994	P-GEAD-1995	Sample0501	total RNA	PAIRED	other	GENOMIC	CH_IP_SEQ	Illumina NovaSeq 6000	P-GEAD-1996	inChIP_H3K9ac_Foxp3posi_RBPJ_MT_rep1	DRX484409	DRR500322	sequencing assay	DRR500322	P-GEAD-1997	DRR500322.tar.gz	Foxp3-positive Tregs	H3K9ac	F235A/L362A mutant RBPJ-AM
@@18@@Sample0501	Sample0501	Homo sapiens	9606	not collected	Cellular Technology Limited	not collected	not collected	not collected	healthy_mixture_7	not collected	Peripheral Blood Mononuclear Cells	SAMD00641098	Sample_inChIP_RBPJ_MT	Naive CD4 Tconv cells were sorted from PBMC (Day 0). Cells were stimulated with plate-bound anti-human CD3 (10 ug/mL; clone UCHT1) and anti-human CD28 (5 ug/mL; clone CD28.2). Cells were transduced with titrated lentivirus encoding mutant RBPJ 24 hours post-stimulation (Day 1). At Day 3, cells were collected and resuspended with freshly prepared medium including 500 IU/mL of hIL-2 (Day 3) and expanded for 6 days. CD4 Tconv cells were stimulated for 72 hours using Dynabeads Human T-Activator CD3/CD28 (Thermo Fisher, #11131D) at a 1:1 ratio and supplemented with 500 IU/mL of hIL-2 (R&D Systems), 5 ng/mL of hTGF-b (R&D Systems), 10 ug/mL of Ascorbate (Sigma-Aldrich), 10 nM of ATRA (Sigma-Aldrich), 5 ug/mL of anti-hIFN-g, -hIL-4, -hIL-6 and -hTNF-a (BioLegend) antibodies and 5 ug/mL of anti-FasL (BioLegend) antibodies in complete culture medium.	P-GEAD-1993	P-GEAD-1994	P-GEAD-1995	Sample0501	total RNA	PAIRED	other	GENOMIC	CH_IP_SEQ	Illumina NovaSeq 6000	P-GEAD-1996	inChIP_H3K9ac_Foxp3posi_RBPJ_MT_rep2	DRX484409	DRR500323	sequencing assay	DRR500323	P-GEAD-1997	DRR500323.tar.gz	Foxp3-positive Tregs	H3K9ac	F235A/L362A mutant RBPJ-AM
@@19@@Sample0502	Sample0502	Homo sapiens	9606	not collected	Cellular Technology Limited	not collected	not collected	not collected	healthy_mixture_8	not collected	Peripheral Blood Mononuclear Cells	SAMD00641099	Sample_inChIP_RBPJ_WT	Naive CD4 Tconv cells were sorted from PBMC (Day 0). Cells were stimulated with plate-bound anti-human CD3 (10 ug/mL; clone UCHT1) and anti-human CD28 (5 ug/mL; clone CD28.2). Cells were transduced with titrated lentivirus encoding WT RBPJ 24 hours post-stimulation (Day 1). At Day 3, cells were collected and resuspended with freshly prepared medium including 500 IU/mL of hIL-2 (Day 3) and expanded for 6 days. CD4 Tconv cells were stimulated for 72 hours using Dynabeads Human T-Activator CD3/CD28 (Thermo Fisher, #11131D) at a 1:1 ratio and supplemented with 500 IU/mL of hIL-2 (R&D Systems), 5 ng/mL of hTGF-b (R&D Systems), 10 ug/mL of Ascorbate (Sigma-Aldrich), 10 nM of ATRA (Sigma-Aldrich), 5 ug/mL of anti-hIFN-g, -hIL-4, -hIL-6 and -hTNF-a (BioLegend) antibodies and 5 ug/mL of anti-FasL (BioLegend) antibodies in complete culture medium.	P-GEAD-1993	P-GEAD-1994	P-GEAD-1995	Sample0502	total RNA	PAIRED	other	GENOMIC	CH_IP_SEQ	Illumina NovaSeq 6000	P-GEAD-1996	inChIP_H3K9ac_Foxp3posi_RBPJ_WT_rep1	DRX484410	DRR500324	sequencing assay	DRR500324	P-GEAD-1997	DRR500324.tar.gz	Foxp3-positive Tregs	H3K9ac	wild-type RBPJ-AM
@@20@@Sample0502	Sample0502	Homo sapiens	9606	not collected	Cellular Technology Limited	not collected	not collected	not collected	healthy_mixture_8	not collected	Peripheral Blood Mononuclear Cells	SAMD00641099	Sample_inChIP_RBPJ_WT	Naive CD4 Tconv cells were sorted from PBMC (Day 0). Cells were stimulated with plate-bound anti-human CD3 (10 ug/mL; clone UCHT1) and anti-human CD28 (5 ug/mL; clone CD28.2). Cells were transduced with titrated lentivirus encoding WT RBPJ 24 hours post-stimulation (Day 1). At Day 3, cells were collected and resuspended with freshly prepared medium including 500 IU/mL of hIL-2 (Day 3) and expanded for 6 days. CD4 Tconv cells were stimulated for 72 hours using Dynabeads Human T-Activator CD3/CD28 (Thermo Fisher, #11131D) at a 1:1 ratio and supplemented with 500 IU/mL of hIL-2 (R&D Systems), 5 ng/mL of hTGF-b (R&D Systems), 10 ug/mL of Ascorbate (Sigma-Aldrich), 10 nM of ATRA (Sigma-Aldrich), 5 ug/mL of anti-hIFN-g, -hIL-4, -hIL-6 and -hTNF-a (BioLegend) antibodies and 5 ug/mL of anti-FasL (BioLegend) antibodies in complete culture medium.	P-GEAD-1993	P-GEAD-1994	P-GEAD-1995	Sample0502	total RNA	PAIRED	other	GENOMIC	CH_IP_SEQ	Illumina NovaSeq 6000	P-GEAD-1996	inChIP_H3K9ac_Foxp3posi_RBPJ_WT_rep2	DRX484410	DRR500325	sequencing assay	DRR500325	P-GEAD-1997	DRR500325.tar.gz	Foxp3-positive Tregs	H3K9ac	wild-type RBPJ-AM
@@21@@Sample0502	Sample0502	Homo sapiens	9606	not collected	Cellular Technology Limited	not collected	not collected	not collected	healthy_mixture_8	not collected	Peripheral Blood Mononuclear Cells	SAMD00641099	Sample_inChIP_RBPJ_WT	Naive CD4 Tconv cells were sorted from PBMC (Day 0). Cells were stimulated with plate-bound anti-human CD3 (10 ug/mL; clone UCHT1) and anti-human CD28 (5 ug/mL; clone CD28.2). Cells were transduced with titrated lentivirus encoding WT RBPJ 24 hours post-stimulation (Day 1). At Day 3, cells were collected and resuspended with freshly prepared medium including 500 IU/mL of hIL-2 (Day 3) and expanded for 6 days. CD4 Tconv cells were stimulated for 72 hours using Dynabeads Human T-Activator CD3/CD28 (Thermo Fisher, #11131D) at a 1:1 ratio and supplemented with 500 IU/mL of hIL-2 (R&D Systems), 5 ng/mL of hTGF-b (R&D Systems), 10 ug/mL of Ascorbate (Sigma-Aldrich), 10 nM of ATRA (Sigma-Aldrich), 5 ug/mL of anti-hIFN-g, -hIL-4, -hIL-6 and -hTNF-a (BioLegend) antibodies and 5 ug/mL of anti-FasL (BioLegend) antibodies in complete culture medium.	P-GEAD-1993	P-GEAD-1994	P-GEAD-1995	Sample0502	total RNA	PAIRED	other	GENOMIC	CH_IP_SEQ	Illumina NovaSeq 6000	P-GEAD-1996	inChIP_H3K9ac_Foxp3posi_RBPJ_WT_rep3	DRX484410	DRR500326	sequencing assay	DRR500326	P-GEAD-1997	DRR500326.tar.gz	Foxp3-positive Tregs	H3K9ac	wild-type RBPJ-AM